• Publications
  • Influence
CD4+ count-guided interruption of antiretroviral treatment.
Episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antireteviral therapy, largely as a consequence of lowering theCD4+ cell count and increasing the viral load. Expand
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
No significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo, and serious adverse events were similar in the two groups. Expand
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
Initiation of ART at CD4+ cell counts >350 cells/ microL compared with <250 cells/microL may reduce both OD and serious non-AIDS events and require validation in a large, randomized clinical trial. Expand
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study
25(OH)D deficiency was frequent in HIV-infected persons (83% on combined antiretroviral therapy), and was independently associated with a higher risk of mortality and AIDS events. Expand
Sequence Analysis of In Vivo Defective Interfering-Like RNA of Influenza A H1N1 Pandemic Virus
  • K. Saira, Xudong Lin, +17 authors E. Ghedin
  • Medicine, Biology
  • Journal of Virology
  • 15 May 2013
Several subgenomic viral RNAs from human nasopharyngeal specimens infected with the influenza A(H1N1)pdm09 virus are characterized using a sequencing approach, with the majority of the defective RNAs generated from the PB2 (segment 1) of the polymerase complex, followed by PB1 and PA. Expand
Interleukin-2 therapy in patients with HIV infection.
Despite a substantial and sustained increase in the CD4+ cell count, as compared with antiretroviral therapy alone, interleukin-2 plus antireteviral therapy yielded no clinical benefit in either study. Expand
Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina
Levels of primary resistance in Buenos Aires are still low, despite a long history of ARV delivery and high coverage levels, and evidence for the transmission of the K103N mutation among the drug-naive population is revealed. Expand
HIV type 1 genetic diversity surveillance among newly diagnosed individuals from 2003 to 2005 in Buenos Aires, Argentina.
CRF16_A2D and a new line of subtype C (of Senegalese origin) seem to be successfully established and are now spreading in Buenos Aires. Expand
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial
It is suggested that a reduced dose of 400 mg efavirenz is non-inferior to the standard dose of 600 mg, when combined with tenofovir and emtricitabine during 48 weeks in ART-naive adults with HIV-1 infection. Expand
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
It is confirmed that efavirenz 400 mg is non-inferior to the standard dose of 600 mg compared with the standard 600 mg dose combined with tenofovir and emtricitabine as first-line HIV therapy. Expand